Company intelligence / Profile preview
Alpha Fusion, Inc.
Osaka, Osaka Prefecture, Japanalpha-fusion.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Alpha Fusion is advancing its pipeline and has made significant progress since Series A funding in May 2023, including development of its first pipeline for Thyroid Cancer. The company is preparing for company-sponsored clinical trials and GMP-grade Astatine drug production.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsTargeted Alpha Therapy (TAT)Astatine (At-211) based therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Osaka UniversityJapan Science and Technology Agency (JST)collaboration with cyclotrons for supply chain
Beyond the preview
Go deeper on Alpha Fusion, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha Fusion, Inc..